Kezar Life Sciences KZR Income Statement (2017-2026)

KZR
$7.29 +0.00 (+0.00%)
At close: May 11, 2026 · 4:00 PM EDT
Income Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
4.81M4.86M5.63M5.96M6.83M6.84M6.85M7.08M7.25M7.27M7.28M7.28M7.29M7.30M7.30M7.31M7.32M7.32M7.33M7.37M
Revenue & cost
Revenue (Quarter)
7.00M
Operating items
Research & Development (Quarter)
9.34M10.53M9.78M10.94M11.35M13.86M14.86M18.32M21.00M23.74M22.64M17.17M16.30M16.24M16.03M12.18M9.58M6.91M5.08M1.54M
Selling, General & Administrative (Quarter)
3.67M3.97M4.32M4.93M4.98M5.07M5.17M6.21M5.79M8.79M5.76M6.54M5.60M5.71M5.54M5.45M5.02M4.80M3.25M5.21M
Restructuring Costs (Quarter)
6.20M1.48M-0.01M1.60M0.60M
Other Operating Expenses (Quarter)
-0.01M5.24M0.01M
Operating Expenses (Quarter)
13.01M14.50M14.10M15.88M16.32M18.93M20.03M24.52M26.78M32.53M34.59M23.71M23.38M21.95M21.56M17.63M14.60M11.71M15.16M7.37M
Operating Income (Quarter)
-13.01M-14.50M-14.10M-15.88M-16.32M-18.93M-20.03M-24.52M-26.78M-25.53M-34.59M-23.71M-23.38M-21.95M-21.56M-17.63M-14.60M-11.71M-15.16M-7.37M
EBIT (Quarter)
-13.01M-14.50M-14.10M-15.88M-16.32M-18.93M-20.03M-24.52M-26.78M-25.53M-34.59M-23.71M-23.38M-21.95M-21.56M-17.63M-14.60M-11.71M-15.16M-7.37M
Non-operating items
Interest & Investment Income (Quarter)
-0.00M-0.01M2.45M2.24M2.04M1.73M1.42M1.20M1.03M0.80M0.61M
Non Operating Income (Quarter)
0.05M0.04M0.05M0.11M0.41M1.39M2.20M2.69M2.86M2.82M2.73M2.45M2.24M2.04M
Net income details
EBT (Quarter)
-20.41M-40.79M-14.17M-16.54M-39.60M-44.25M-20.43M-25.13M-28.02M-26.18M-34.75M-30.63M-21.89M-20.67M-20.22M-16.56M-17.84M-14.13M-13.94M-7.73M
Profit After Tax (Quarter)
-12.96M-14.46M-14.21M-16.02M-16.19M-17.85M-18.18M-22.20M-24.31M-23.10M-32.26M-21.66M-21.55M-20.31M-20.22M-16.56M-13.70M-11.23M-14.55M-5.76M
Income from Continuing Operations (Quarter)
-20.41M-40.79M-14.17M-16.54M-39.60M-44.25M-20.43M-25.13M-28.02M-26.18M-34.75M-30.63M-21.89M-20.67M-20.22M-16.56M-17.84M-14.13M-13.94M-7.73M
Consolidated Net Income (Quarter)
-20.41M-40.79M-14.17M-16.54M-39.60M-44.25M-20.43M-25.13M-28.02M-26.18M-34.75M-30.63M-21.89M-20.67M-20.22M-16.56M-17.84M-14.13M-13.94M-7.73M
Income towards Parent Company (Quarter)
-20.41M-40.79M-14.17M-16.54M-39.60M-44.25M-20.43M-25.13M-28.02M-26.18M-34.75M-30.63M-21.89M-20.67M-20.22M-16.56M-17.84M-14.13M-13.94M-7.73M
Net Income towards Common Stockholders (Quarter)
-20.41M-40.79M-14.17M-16.54M-39.60M-44.25M-20.43M-25.13M-28.02M-26.18M-34.75M-30.63M-21.89M-20.67M-20.22M-16.56M-17.84M-14.13M-13.94M-7.73M
Additional items
EPS (Basic) (Quarter)
-3.93-7.84-2.69-2.73-6.16-6.13-3.03-3.47-3.87-3.60-4.79-4.21-3.00-2.83-2.77-2.27-2.44-1.93-1.91-1.05
EPS (Diluted) (Quarter)
-3.93-7.84-2.69-2.73-6.16-6.13-3.03-3.47-3.87-3.60-4.79-4.21-3.00-2.83-2.77-2.27-2.44-1.93-1.91-1.05
Shares Outstanding (Quarter)
5.19M5.20M5.28M6.06M6.43M7.22M6.74M7.23M7.25M7.27M7.26M7.28M7.28M7.30M7.29M7.31M7.31M7.32M7.32M7.34M
Shares Outstanding (Diluted) (Quarter)
5.19M5.20M5.28M6.06M6.43M7.22M6.74M7.23M7.25M7.27M7.26M7.28M7.28M7.30M7.29M7.31M7.31M7.32M7.32M7.34M
EBITDA (Quarter)
-13.01M-14.50M-14.10M-15.88M-16.32M-18.93M-20.03M-24.52M-26.78M-25.53M-34.59M-23.71M-23.38M-21.95M-21.56M-17.63M-14.60M-11.71M-15.16M-7.37M
Interest Expenses (Quarter)
7.39M26.28M0.07M0.66M23.28M25.32M0.40M0.60M1.24M0.65M0.16M9.37M0.74M0.76M0.39M0.35M4.44M3.44M-0.42M0.97M